Optimizing Treatment of Chronic Lymphocytic Leukemia
Presented by Sandra E. Kurtin, PhD, ANP-C, AOCN®
From The University of Arizona Cancer Center, Tucson, Arizona
J Adv Pract Oncol 2021;12(3):325–328 |
© 2021 Harborside™
During JADPRO Live Virtual 2020, Sandra Kurtin, PhD, ANP-C, AOCN®, described personalization of the treatment of chronic lymphocytic leukemia (CLL) using molecular attributes of the disease, as well as patient characteristics. Dr. Kurtin discussed front-line treatment in previously untreated patients, treatment for relapsed or refractory CLL, and how to prevent, mitigate, and manage adverse events in order to optimize treatment.
For access to the full length article, please sign in